Larazotide acetate is a peptide that tightens the intestinal barrier by blocking zonulin, a protein that loosens the junctions between gut cells, and is being studied primarily for celiac disease and other chronic inflammatory conditions.
What it does
The gut lining is held together by tight junctions (TJs) — protein structures that act like seals between intestinal cells, controlling what crosses from the gut into the bloodstream. When TJs loosen abnormally, a state called increased intestinal permeability (sometimes called 'leaky gut'), bacterial fragments, partially digested proteins, and other inflammatory triggers can slip through. Zonulin is the main signaling protein that regulates TJ tightness; when it's overactive, the barrier opens PubMed 39252622.
Larazotide acetate is a zonulin antagonist — it competes with zonulin at its receptor, blocking the signal that would otherwise loosen TJs PubMed 33881350. Rather than suppressing the immune system broadly, it works upstream, at the barrier itself. By keeping TJs intact, it aims to reduce the flood of antigens (foreign substances triggering immune reactions) that drives chronic inflammation PubMed 33397225.
This mechanism is relevant across several conditions. In celiac disease, gliadin peptides from gluten trigger zonulin release, which opens the barrier and lets more gliadin through — a self-amplifying cycle PubMed 33707052. The same dysregulation has been implicated in inflammatory bowel disease and multiple sclerosis PubMed 39252622. Larazotide targets this shared upstream step rather than any single disease pathway PubMed 35887067.
What the evidence shows
Celiac disease (gluten exposure management) Multiple small-to-moderate randomized controlled trials in humans; no large phase III approval yet
Several randomized, double-blind, placebo-controlled trials have tested larazotide in celiac disease patients exposed to dietary gluten. Across these studies, larazotide at doses around 0.5 mg three times daily reduced gastrointestinal symptom scores and markers of intestinal permeability compared to placebo NCT00620451 NCT00362856. A 2019 review noted it as the furthest-advanced non-dietary therapy for celiac disease in the pipeline PubMed 31157194. Safety in healthy volunteers was also assessed in early trials NCT00386490. The effect on gut permeability is consistent; symptom relief is meaningful but modest, and it does not eliminate immune activation from gluten — it blunts the barrier breach that amplifies it PubMed 33881350.
Acute liver failure (intestinal component) Rodent data only; no human trials
In a rat model of acute liver failure, larazotide acetate reduced intestinal damage and attenuated liver injury, suggesting that gut barrier protection limits the bacterial translocation that worsens liver outcomes PubMed 34791921. This is mechanistically plausible — compromised gut barriers in liver failure allow bacterial products into portal circulation — but the step to human data has not been taken.
Broader chronic inflammatory conditions (IBD, MS, autoimmunity) Theoretical and early-stage; mostly mechanistic reviews and animal models
Zonulin dysregulation has been documented across inflammatory bowel disease, multiple sclerosis, and other autoimmune conditions, making larazotide a conceptual candidate for each PubMed 39252622 PubMed 33397225. One review catalogued the therapeutic rationale across acute and chronic inflammatory diseases PubMed 33397225. Direct clinical trial data outside of celiac disease is sparse. The mechanism is credible; the evidence for clinical benefit in these indications is not yet there PubMed 35887067.
How it's used
In clinical trials for celiac disease, the most-studied dose has been 0.5 mg taken orally three times daily, timed around meals during periods of expected gluten exposure NCT00620451 PubMed 33881350. Some trials explored a range from 0.25 mg to 4 mg per dose. The oral route is appropriate given the target is the intestinal lining itself. Half-life has not been publicly specified in standard references. Dosing for other indications, if any protocol exists, would differ and has no established standard. In studies and self-reported protocols, doses range from 0.25 mg to 4 mg orally per dose; the 0.5 mg three-times-daily schedule is the most clinically tested.
Side effects and safety
Across trials, larazotide has been well tolerated. Reported mild effects include GI upset, headache, and fatigue NCT00362856 NCT00386490. Because the drug modulates immune-barrier interactions rather than broadly suppressing immunity, infection risk appears lower than with conventional immunosuppressants — but immunomodulation at the barrier level means caution is warranted in people with active infections or who are already immunosuppressed PubMed 33397225. Severe allergic reactions have been listed as a potential risk. Long-term safety data are limited; most trials ran for weeks to months, not years. The consequences of sustained TJ modulation over years in humans are not well characterized.
Bottom line
Larazotide acetate has the most credible and best-supported use case in celiac disease, where human trial data show consistent, if modest, barrier protection during gluten exposure NCT00620451 PubMed 33881350. For other inflammatory conditions, the mechanism is interesting but evidence is currently thin. It is not an approved drug in most jurisdictions, and anyone considering it outside a clinical trial context should understand that the evidence base, while promising, is still incomplete.